NEW HAVEN, Conn., October 1, 2019 (Newswire.com) - Dr. Jeff Geschwind is pleased to announce that he will be giving a lecture at this years’ Symposium on Clinical Interventional Oncology, taking place on October 11th through the 13th in Miami, Florida. Dr. Geschwind will be presenting his lecture on October 11 at 2:20 p.m. during the second session highlighting trends in Interventional Oncology (IO). His presentation will be an overview of what Artificial Intelligence (AI) means for the future of IO.
Jeff Geschwind has extensive knowledge of how big data and AI have impacted the developing field of IO. He has performed intensive past research with other clinical physicians on how the strength of the conclusions made in IO is largely dependent on the quality of the data collected. In Oncology, where large clinical trials are the norm, data can be rapidly collected and inferred to come to strong conclusions. However, with Interventional Oncology, the data needed is not as robust, making it more difficult to leap to similar clinical decisions.
Dr. Jeff Geschwind is joined by over 40 world-renowned experts giving 80+ practical IO presentations at this years’ symposium. The symposium is directed by Doctors Ripal Gandhi, Ziv Haskal, Costantino Peña, Daniel Sze, and Alda Tam. During the course of the three-day conference, a plethora of topics are to be discussed, all relating to Interventional Technology. Some of the topics include, but are not limited to, techniques, trends, technologies and procedures involved in IO. The topics are then broken into smaller lectures and recorded cases.
About Dr. Jeff Geschwind:
Dr. Jeff Geschwind is a medical pioneer in the fields of radiology and oncology. He has been involved in a number of medical organizations, including the American Society of Clinical Oncology, the Hepatobiliary Task Force of the National Cancer Institute, the Radiological Society of North America, the American Association for Cancer Research, and the International Liver Cancer Association. Today, Dr. Geschwind remains an active member of the Society of Interventional Radiology and the Cardiovascular and Interventional Radiology Society of Europe.
Jeff Geschwind recently became the Director of Oncology at USA Vein Clinics and USA Fibroid and Vascular Centers. His focus is largely on high-level clinical research of new technologies surrounding Interventional Oncology and Radiology. He is committed to developing cancer centers for patients to find effective treatment from the world’s finest physicians, using cutting-edge technology to provide minimally invasive procedures.
It is because of his passion for clinical research and technology that Dr. Jeff Geschwind has made such a considerable contribution to the field of liver cancer, both in terms of basic, translational, and therapeutic developments. He has published almost 300 scientific manuscripts in the most highly rated medical journals and treated over 2,000 patients afflicted by liver cancer in his career.
Source: Dr. Jeff Geschwind